公开(公告)号：EP3603667A1

公开(公告)日：2020-02-05

申请号：EP19172758.5

申请日：2014-03-13

申请人： Takeda Vaccines, Inc.

发明人： STINCHCOMB, Dan ,  LIVENGOOD, Jill ,  VARGA, Laszlo

IPC分类号： A61K39/12

摘要： Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.

公开(公告)号：EP2968515B1

公开(公告)日：2019-05-08

申请号：EP14717940.2

申请日：2014-03-13

申请人： Takeda Vaccines, Inc.

发明人： STINCHCOMB, Dan T. ,  LIVENGOOD, Jill A. ,  VARGA, Laszlo

IPC分类号： A61K39/12 ,  C12N7/00

公开(公告)号：EP2968515A1

公开(公告)日：2016-01-20

申请号：EP14717940.2

申请日：2014-03-13

申请人： Takeda Vaccines, Inc.

发明人： STINCHCOMB, Dan T. ,  LIVENGOOD, Jill A. ,  VARGA, Laszlo

IPC分类号： A61K39/12

CPC分类号： A61K39/12 ,  A61K47/22 ,  A61K47/26 ,  A61K47/42 ,  A61K2039/5254 ,  C12N2770/36134

摘要： Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.